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Abstract
Introduction Hes-6 is a member of the basic helix-loop-helix
(bHLH) family of transcription factors, and its overexpression
has been reported in metastatic cancers of different origins.
Hes-6 has been described as an inhibitor of Hes-1 during
neuronal development, although its function in cancer is not
known. In this study, we investigated the function of Hes-6 in
breast cancer and tested the hypothesis that Hes-6 enhances
breast cancer cell proliferation and is regulated by estrogen.
Methods To investigate the function of Hes-6, T47D cells stably
expressing Hes-6 were generated by lentiviral transduction, and
conversely, siRNA also was used to knock down Hes-6
expression in breast cancer cells. The Hes-6-expressing T47D
cells were transplanted into immunodeficient mice to study
effects on tumor growth.
Results We found that Hes-6 expression was significantly
higher in the high-grade, estrogen receptor (ER)α-negative
SKBR3 and MDA-MB-231 cells compared with the ERα-
positive, non-metastasizing T47D and MCF-7 breast carcinoma
cells. Moreover, the level of Hes-6 mRNA was 28 times higher
in breast cancer samples compared with normal breast samples.
In Hes-6-expressing T47D cells, Hes-6 ectopic expression was
shown to stimulate cell proliferation in vitro as well as breast
tumor growth in xenografts. Moreover, expression of Hes-6
resulted in induction of E2F-1, a crucial target gene for the
transcriptional repressor Hes-1. Consistently, silencing of Hes-
6 by siRNA resulted in downregulation of E2F-1 expression,
whereas estrogen treatment caused induction of Hes-6 and
downstream targets hASH-1 and E2F-1 in MCF-7 cells.
Conclusions Together, the data suggest that Hes-6 is a
potential oncogene overexpressed in breast cancer, with a
tumor-promoting and proliferative function. Furthermore, Hes-6
is a novel estrogen-regulated gene in breast cancer cells. An
understanding of the role and regulation of Hes-6 could provide
insights into estrogen signaling and endocrine resistance in
breast cancer and, hence, could be important for the
development of novel anticancer drugs.
Introduction
The majority of breast cancer cells are dependent on estro-
gens to support their survival and proliferation [1]. 17β-Estra-
diol (E2) is the most potent estrogen as well as the
predominant estrogen in premenopausal women. In breast
cancer, two main types of estrogen receptors (ERs) exist, ERα
and ERβ [2-4]. As shown by in vitro experiments, ERα medi-
ates the proliferative effect of estrogens, whereas ERβ inhibits
proliferation [5] in breast cancer cells. In T47D and MCF-7
breast cancer cells, ERα promotes proliferation by stimulating
expression of cell-cycle regulators and through downregula-
tion of the transcriptional repressors, such as Hes-1. Hes-1 is
a member of the basic helix-loop-helix (bHLH) family of tran-
scription factors [6], first described in embryonic develop-
ment, in which Hes-1 inhibits differentiation of developing
neurons. In breast cancer cells, downregulation of Hes-1 is
essential for estrogen-mediated proliferation [7]. Consistently,
forced expression of Hes-1 causes G1-phase cell-cycle arrest.Page 1 of 9
(page number not for citation purposes)
bHLH: basic helix-loop-helix; E2: 17β-estradiol; ER: estrogen receptor; hASH-1: human achaete-scute complex homologue 1; Hes: hairy and 
enhancer of split; SCID: severe immunodeficiency.
Breast Cancer Research    Vol 11 No 6    Hartman et al.The transcriptional activator E2F-1 is an important cell-cycle
regulator, stimulating the G1/S-phase transition by activating
the transcription of other cell-cycle genes [8]. We earlier iden-
tified E2F-1 as a crucial transcription factor directly inhibited
by Hes-1 at the transcriptional level in breast cancer [9]. Hes-
1 binds to the promoter region of E2F-1, thereby repressing
its transcription. Based on our findings, we believe that E2F-1
is a central factor in Hes-1-mediated inhibition of proliferation.
Hes-6 is a member of the same family of transcription factors
as Hes-1 but functions as a posttranslational inhibitor of Hes-
1 [10,11]. Hes-6 forms a heterodimer with Hes-1, thereby pre-
venting its association with transcriptional co-repressors. Hes-
6 was first discovered in nervous tissue, but its expression in
the mammary gland is not known. Despite its role as an inhib-
itor of Hes-1, the function of this potential oncogene remains
unclear.
Human achaete-scute complex homologue 1 (hASH1) is
another member of the bHLH-family. In contrast to Hes-1,
hASH-1 functions as a transcriptional activator, inducing tran-
scription through E-boxes, and is negatively regulated by Hes-
1 at the promoter level [12,13].
Despite being a potential tumor suppressor in vitro, no signifi-
cant difference in its expression between breast cancer and
normal tissue has been found. Therefore, another cofactor is
probably involved in the regulation of Hes-1 action.
In an experimental mouse model of colon cancer, several
genes were upregulated in metastases, but the only gene that
was upregulated in all metastases compared with their primary
tumor was Hes-6. Furthermore, the authors showed that Hes-
6 is upregulated in several types of human cancers compared
with normal tissue [14]. Recently, Hes-6 and hASH-1 have
been reported to be overexpressed in high-grade prostate
cancer and were suggested to be involved in neuroendocrine
development of the cancer cells to an aggressive phenotype
[15].
By expressing Hes-6 in the breast cancer cell-line T47D, we
studied its role in tumor growth and proliferation. In addition,
we investigated its effects on expression of the Hes-1 target
gene E2F-1 and its potential involvement in ER signaling.
Because Hes-6 antagonizes Hes-1, our hypothesis is that




T47D and MCF-7 cells were cultured in DMEM/F12 mixed
1:1, whereas MDA-MB-231 and SK-BR3 cells were cultured
in RPMI 1640. Medium was supplemented with 5% fetal
bovine serum (FBS). For synchronization of T47D and MCF-7
cells, the medium was changed to phenol red-free DMEM/F12
mixed 1:1 and DMEM, respectively, supplemented with 5%
dextran-coated charcoal-treated FBS (DCC) for 24 hours; The
serum was then reduced to 0.5% DCC before 10 nM ICI
182,780 (ICI) (Tocris, St. Louis, MO, USA) was added.
Lentivirus vectors and infection of T47D cells
The pLenti6/V5-D-FLAG Hes-6 vector was constructed by
cloning a PCR-amplified fragment of Hes-6 into the EcoRI site
of pcDNA3-FLAG and then amplifying the FLAG-tagged Hes-
6 with primers flanked by SpeI sites for cloning into the SpeI
site of pLenti6/V5-D.
Empty pLenti6/V5-D vector, without Hes-6 cDNA, was used
as the "mock" control. Lentivirus was produced with the ViraP-
ower Lentivirus Expression system. The titer of the virus was
estimated according to instructions (Invitrogen, Carlsbad, CA,
USA). T47D cells were seeded onto six-well plates at a density
of 200,000 cells per well. The next day, lentivirus at 4 m.o.i
was added in 1 ml of growth medium supplemented with 6 μg
of hexadimethrine bromide (Polybrene) (Sigma, St. Louis, MO,
USA). After 24 hours at 37°C, the cells were washed, and 2
ml of normal growth medium was added. Blasticidine (Invitro-
gen, Carlsbad, CA, USA) was added to 10 μg/ml after another
24 hours, and the cells were then incubated for another 5 days
at 37°C. Non-infected dead cells were washed off, and the
remaining cells were trypsinized and expanded for further anal-
ysis. All experiments were performed with polyclonal Hes-6-
expressing cells.
Cell-proliferation assay
Then 2,000 cells were plated per well in 96-well plates and
cultured in 2% DCC. The next day, cells were synchronized by
using 10 nM ICI 182780 (Tocris, St. Louis, MO, USA) for 24
hours; the following day, cells were washed once with PBS,
and the medium was changed to include the respective treat-
ments (10 nM E2 or 10 nM ICI). After 5 days of incubation, the
cell viability was assayed by using the MTS kit (Promega, Mad-
ison, WI, USA) (CellTiter 96 Aqueous Non-Radioactive Cell
Proliferation Assay). The absorbance was measured at 490
nm.
Transfection of siRNA to HES-6
The 50,000 cells/well were seeded onto a 24-well plate. The
next day, growth medium containing 2% DCC was added.
After another 24 hours, the cells were transfected with 50 nM
siRNA targeting LUC or Hes-6 by using DharmaFECT 2 trans-
fection medium. On the next day, medium containing 0.5%
DCC was added, and after another 24 hours, 10 nM E2 was
added to half of the wells. Expression of Hes-6 and E2F-1 was
analyzed by using real-time PCR 24 hours after start of treat-
ment.
Western immunoblotting and antibodies
T47D-Hes-6/mock transduced cells were plated and grown in
150-mm plates until 30% confluence was reached. At timePage 2 of 9
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extraction were done at 24 hours according to standard pro-
tocol. SDS-PAGE was performed as described [16]. The fol-
lowing primary antibodies were used: E2F-1 (sc-251, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), β-actin (Sigma,
St. Louis, MO, USA), and Hes-6 (rabbit antibody raised in our
laboratory).
RNA extraction and real-time PCR
RNA extraction was performed with TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) and chloroform extraction, according to
standard protocol. cDNA synthesis was performed with the
First Strand System according to standard protocol (Nordic
Bioservice AB, Stockholm, Sweden). Real-time PCR was per-
formed with NBS Mastermix (Nordic Bioservice AB, Stock-
holm, Sweden). The following primers and probes were used:
18s rRNA F: 5'-CCT GCG GCT TAA TTT GAC TCA-3', R: 5'-
AGC TAT CAA TCT GTC AAT CCT GTC C-3' as a reference
gene. The real-time PCR reactions were performed in an ABI
PRISM 7500 (Applied Biosystems, Carlsbad, CA, USA) with
optimized conditions for NBS Mastermix: 50°C for 2 minutes,
95°C for 10 minutes, followed by 40 to 50 cycles at 95°C for
15 seconds and 60°C for 50 seconds. The optimal concentra-
tion of primers was determined in preliminary experiments, and
all SYBR-Green primer pairs were checked with dissociation-
curve analysis.
Experimental animals and xenograft model
Mice were housed in filter-top cages under sterile conditions
at the animal facility at Karolinska University Hospital, Hud-
dinge. One confluent 150-cm2 Falcon cell-culture flask per
mouse with T47D-Hes-6 or T47D-mock cells was trypsinized
and diluted with 200 μl normal medium + 200 μl Matrigel (BD
Falcon, San Jose, CA, USA). The cell suspension (300 μl) was
injected into the abdominal fat close to the mammary tissues
of 9- to 12-week-old pathogen-free SCID/beige mice
(Taconic, Lillie Skensved, Denmark) on day 0. E2 pellets, 0.72
mg/pellet (IRA, Sarasota, FL, USA), were injected subcutane-
ously in the neck with a pellet trochar (IRA, Sarasota, FL,
USA). After 7 and 14 days, the mice were killed, and the tumor
volume was measured with calipers according to the formula
length × width × height. All tumors were fixed in 4% parafor-
maldehyde and stored in 75% ethanol, and tumors of sufficient
size also were prepared for mRNA extraction as described
later. Animal experiments were approved by Swedish Board of
Agriculture, reference number: S 27-08, including approved
animal welfare, experimental protocol, and animal toxicology.
Human breast cancer samples
Human breast samples were obtained from breast cancer sur-
gery performed at the Hammersmith Hospital, London, UK,
between the years 1985 and 1998. All tissues were made
anonymous for the researchers, and identities could not be
connected to individual samples. To each tissue sample, the
following parameters were attached: Tumor size, tumor stage,
age at diagnosis, age of patient, and menopausal status. The
samples consisted of 28 normal or benign breast tissues (con-
trol) and 38 breast cancer tissues. All tissue samples were
homogenized, RNA-extracted, and subsequently analyzed
with real-time PCR according to procedure. The study was
ethically approved by Forskningsetiska nämnden, Stockholm,
reference number 04-951/1. All tumor samples were anony-
mous and cannot be tracked to the corresponding patient;
therefore, an informed consent from each patient was deemed
unnecessary by the ethics committee.
Ki67-immunohistochemistry
To examine the number of proliferating cells in tumor
xenografts, immunohistochemistry with a Ki-67 antibody was
performed. Antigen retrieval was done by microwave boiling in
0.01 M citric acid (pH 6.0) for 120 seconds, and then slides
were left undisturbed for 20 minutes. Endogenous peroxidase
activity was blocked by incubating sections shaking in 3%
hydrogen peroxide in methanol for 10 minutes and then
blocked in 2% bovine serum albumin (BSA) and 0.1% NP40
for 1 hour at room temperature. Primary antibody Ki-67 (Dako-
Cytomation, Glostrup, Denmark) was diluted 1:100 in 2%
BSA and 0.1% NP40 and incubated overnight at 4°C. Sec-
tions were then washed consecutively in PBS, 0.1% NP40 for
3 × 5 minutes, followed by incubation with a biotinylated anti-
body BA-9200 1:200 in 0.1% NP40 for 1 h (Vector Laborato-
ries, Burlingame, CA, USA). After this, sections were
incubated in the streptavidin-horseradish peroxidase ABC
complex (Vectastain Elite; Vector Laboratories, Burlingame,
CA, USA) for 1 hour, stained in DAB, and counterstained with
Mayer hematoxylin (Sigma, St. Louis, MO, USA) before dehy-
dration through ethanol, and mounted in Pertex (Histolab,
Gothenburg, Sweden). The number of Ki-67-positive cells was
counted on two independent fields per slide with a 20× objec-
tive. The average number of positive cells and SD were calcu-
lated for each group.
Statistics
Values are expressed as means with 95% confidence inter-
vals. An unpaired, two-tailed t test was used to compare differ-
ences between two groups. One-way ANOVA with Tukey's
multiple-comparisons posttest was used to analyze differ-
ences between three or more groups. Significance is pre-
sented as *P < 0.05, **P < 0.005, ***P < 0.001;
nonsignificant differences are presented as NS.
Results
Elevated levels of Hes-6 have been found in prostate and
colon cancers compared with normal tissue, where the expres-
sion is low. We first performed real-time PCR to determine
Hes-6 mRNA levels in different breast cancer cell lines. The
estrogen-dependent, ERα-positive T47D and MCF-7 cells
contained low levels of Hes-6, in comparison with the more-
aggressive, ERα-negative breast cancer cell lines MDA-MB-Page 3 of 9
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of Hes-6 mRNA (Figure 1a).
We investigated the expression of Hes-6 in normal breast tis-
sue compared with cancer tissue. The expression of Hes-6
mRNA was very low in normal breast specimens. In breast
cancer tissue, however, Hes-6 expression was increased by
more than 28 times compared with that in normal breast spec-
imens (Figure 1b). The cell-cycle regulator E2F-1 was also sig-
nificantly increased in breast cancer samples compared with
normal breast tissue (Figure 1c).
Because Hes-6 is expressed at low levels in ERα+ breast can-
cer cells, we generated stable Hes-6-expressing T47D cells
by lentiviral transduction with a Hes-6 expression vector (Fig-
ure 2a).
We showed previously that Hes-1 represses the proliferation
of breast cancer cells and that E2F-1 is directly inhibited by
Hes-1 at the transcriptional level. The transcription factor E2F-
1 is a central player in the regulation of proliferation and func-
tions by activating transcription of G1/S/G2-phase genes.
Because Hes-6 is an inhibitor of Hes-1, we reasoned that Hes-
6 would affect proliferation as well as E2F-1 expression.
T47D cells expressing Hes-6 or with empty vector as control
(T47D-Hes-6/control) were synchronized and incubated with-
out E2 for 24 hours. After 5 days, proliferation assays were per-
formed by incubating the cells with the tetrazolium compound
MTS, and subsequently analyzed by measuring the absorb-
ance of the cell-culture medium at 490 nm (MTS assay).
As shown in Figure 2b, E2 treatment of T47D control cells
increased proliferation by approximately 50%. Expression of
Hes-6 in the absence of E2 also increased proliferation to
about the same extent. E2 treatment of T47D-Hes-6 cells
caused a further stimulation of proliferation by approximately
30%.
Real-time PCR and Western blot were performed on T47D-
Hes-6 or mock cells to investigate the transcriptional effects of
Hes-6. We found that the expression of Hes-6 resulted in
induction of E2F-1 mRNA and protein levels in comparison to
the control (Figure 2c and 2d). The Hes-1 target hASH-1,
which is normally inhibited by Hes-1, was strongly upregulated
at the mRNA level in response to Hes-6 expression (Figure
2e).
Further to study the function of Hes-6 in breast cancer cells
and to determine whether Hes-6 influences tumor growth, we
performed xenograft studies in SCID/beige-immunodeficient
mice. The T47D-Hes-6 or control cells were injected into the
abdominal subcutaneous fat of 12-week-old female mice.
Mice were killed on day 7 or 14, and the tumors were taken
out, measured, and weighed (Figure 3a); representative pic-
tures are shown in Figure 3d. Expression of Hes-6 caused a
significant increase in both tumor weight (Figure 3a-1) and
size (Figure 3a-2) at both 7 and 14 days. To measure the rate
of proliferation in vivo, Ki67-immunohistochemistry was per-
formed on the xenograft sections. Although the proliferation
was high in both groups, the number of Ki67-positive cells was
significantly higher in Hes-6yexpressing xenografts compared
with controls (Figure 3e). RNA was extracted from the tumors
and analyzed with real-time PCR. Whereas the endogenous
level of Hes-6 in the T47D-control tumors was low, a strong
induction of Hes6 was found in the T47D-Hes-6 tumors (Fig-
ure 3b). In addition, E2F-1 was upregulated at the mRNA level
in the Hes-6-expressing tumors compared with the controls
(Figure 3c), in line with the in vitro experiments. Notably, how-
Figure 1
Expression of Hes-6 is increased in breast cancer. (a) Expression of 
Hes-6 mRNA in breast cancer cell lines T47D (bar 1), MCF-7 (bar 2), 
SKBR3 (bar 3), and MDA-MB-231 (bar 4). All experiments were 
repeated twice with similar results. Data are presented as mean values 
of six samples (bars 1, 2, and 3) and five samples (bar 4) ± SEM. 
Expression of Hes-6 mRNA (b) and E2F-1 mRNA (c) in noncancerous 
breast biopsies (bar 1) compared with malignant breast (bar 2). Data 
are presented as mean values of 24 (bars 1) and 28 (bars 2) samples ± 
SEM. Graphs are shown as relative values to bars 1 (100%) of each 
graph. Significance is presented as *P < 0.05; **P < 0.005; ***P < 
0.001. Nonsignificant differences are presented as NS.Page 4 of 9
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compared with the in vitro cultured cells.
Estrogen-bound ERα is an important stimulator of proliferation
in breast cancer cells [5] and is consequently an important tar-
get for endocrine therapy of breast cancer. ERα drives prolif-
eration by stimulating several cell-cycle factors [17], but also
by inhibiting the expression of Hes-1, as described earlier [7].
We wanted to see whether ERα also could influence the
expression of Hes-6. Through measuring Hes-6 mRNA and
protein in E2-treated synchronized MCF-7 cells, we observed
that Hes-6 mRNA was upregulated in response to E2 treat-
ment (Figure 4a), indicating that ERα activates Hes-6 expres-
sion in the presence of E2. E2 treatment also caused a robust
induction of hASH-1 mRNA (Figure 4b). At the protein level,
Hes-6 was induced in response to E2 (Figure 4c). Consist-
ently, treatment with tamoxifen reduced the Hes-6 level dra-
matically.
Finally, we used siRNA against Hes-6 to study whether E2F-1
expression is dependent on Hes-6 expression. Transfection of
MCF-7 cells with 50 nM Hes-6 siRNA reduced Hes-6 mRNA
level in both presence and absence of E2 (Figure 5a). How-
ever, siRNA against Hes-6 did not reduce the E2F-1 mRNA
level in absence of E2, but counteracted the E2-mediated
upregulation of E2F-1 (Figure 5b), compared with the siRNA-
luciferase control.
Figure 2
Hes-6 increases proliferation and E2F-1 transcription in T47D cells. (a) Expression of Hes-6 mRNA in T47D-control (bar 1) and T47D-Hes-6 cells 
(bar 2) cells (three samples/bar). (b) Proliferation assay performed with MTS kit (Promega) after 5 days' incubation ± E2 on synchronized, polyclonal 
T47D-control/Hes-6 cells. T47D-control cells without (bar 1) or with (bar 2) E2, T47D-Hes-6 cells without (bar 3) or with (bar 4) E2 (12 samples/bar). 
(c) Relative E2F-1 mRNA levels in T47D-control (bar 1) and T47D-Hes-6 (bar 2) cells (three samples/bar) in nonsynchronized cells. (d) E2F-1 
(upper lane) and Hes-6 protein (lower lane) in synchronized T47D-control/Hes-6 cells, measured with Western blot. Graphs represent protein inten-
sity of E2F-1 Western blot, analyzed with Biorad software; T47D-control (bar 1) and T47D-Hes-6 at 0 hours (bar 2) in the absence of E2, T47D-con-
trol (bar 3), and T47D-Hes-6 at 24 hours (bar 4) in the presence of E2. (e) Relative hASH-1 mRNA levels in T47D-control (bar 1) and T47D-Hes-6 
(bar 2) cells (three samples/bar) in nonsynchronized cells. Graphs are shown as relative values to bars 1 (100%) of each graph. All graphs are pre-
sented as mean values ± SD. Significance is presented as *P < 0.05; **P < 0.005; and ***P < 0.001.Page 5 of 9
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We previously identified and characterized Hes-1 as an essen-
tial transcription factor in ERα-signaling and a strong inhibitor
of estrogen-stimulated proliferation in breast cancer cells [7].
However, despite several attempts to investigate Hes-1
expression in breast cancer, we have not found any difference
in Hes-1 expression in breast cancer tissues compared with
normal tissues. For this reason, we investigated the expression
of the Hes-1 inhibitor Hes-6 and its potential involvement in
proliferation.
As described in the Introduction, the transcription factor Hes-
6 is a novel Hes-family member, whose only established func-
tion is to inhibit DNA binding of Hes-1, thereby inhibiting Hes-
1 activity. Here we identify Hes-6 as a novel estrogen-regu-
lated gene in breast cancer. Most interestingly, as shown in
Figure 1, Hes-6 is expressed at higher levels in breast cancer
tissue compared with normal breast tissue. This result could
be interpreted in at least two different ways: Hes-6 could be a
marker associated with breast cancer in general, without any
major function. Alternatively, it could mean that Hes-6 is
Figure 3
Hes-6 expression increases the growth of T47D xenografts. (a) Tumor weight (a-1) and volume (a-2) of T47D-control (bars 1, 3) (n = 4 and 5, 
respectively) and T47D-Hes-6 xenografts (bars 2 and 4) (n = 3 and 4, respectively) in SCID/beige mice measured after 7 (bars 1, 2) and 14 days 
(bars 3, 4). Data are presented as mean ± SD. Relative Hes-6 (b) and E2F-1 mRNA-levels (c) in T47D-mock (bar 1) xenografts (set as 100%) and 
T47D-Hes-6 xenografts (bar 2). Data are presented as mean values of eight (bar 1) and six (bar 2) samples ± SD: (d) Representative pictures of 
T47D-Hes-6 xenografts (upper lane) or T47D-mock xenografts (lower lone) grown for 1 week. (e) Number of Ki67-positive cells per visual field (20× 
objective) in control xenografts (bar 1) and Hes-6-expressing xenografts (bar 2). Data are presented as means of eight xenografts per bar. Signifi-
cance is presented as *P < 0.05; **P < 0.005; and ***P < 0.001. Nonsignificant differences are presented as NS.Page 6 of 9
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the progression of breast cancer. In this study, we present evi-
dence that Hes-6 has an important role in the proliferation of
breast cancer cells and in the growth of corresponding
xenografts.
As expected, in parallel to the high levels of Hes-6, we identi-
fied a higher expression of E2F-1 in the breast cancer samples
compared with that in the normal breast tissue samples (Fig-
ure 1c), in agreement with what has been described by other
researchers. Based on our findings, we suggest that
increased E2F-1 levels could be a result of regulation by the
Hes-1/Hes-6 system.
As shown in Figure 1a, Hes-6 mRNA also was higher in the
aggressive, ERα-negative cell lines SKBR3 and MDA-MB231
than in the ERα-positive T47D and MCF-7 cells. Because
Hes-6 has been identified as a marker for aggressive, high-
grade cancers of other origins than the breast, Hes-6 also
could be associated with high proliferation and aggressive-
ness in breast cancer. Conversely, this finding is in contrast to
our experiments implicating Hes-6 as a gene expressed in
response to ERα stimulation (Figure 4). It is likely that other,
ER-independent signaling pathways also regulate Hes-6
expression. This is exemplified by the nerve growth factor
activity of Hes-1 during differentiation of the pheochromocy-
toma cell line PC12 [18]. Because genetic abnormalities are
common in breast cancer [19], it also is possible that the DNA
regions harboring the Hes-6 gene are amplified in some breast
cancer cells, thereby causing constantly increased Hes-6 lev-
els.
The function of Hes-6 has been studied extensively within the
developing nervous system [10,11]. Moreover, the expression
of Hes-6 in different tissues has been reported. Nevertheless,
Figure 4
Hes-6 is expressed in response to ERα stimulation in MCF-7 cells. (a) 
Relative Hes-6 mRNA levels in synchronized, non-E2-treated MCF-7 
cells (bar 1), non-E2-treated MCF-7 cells after 24 hours (bar 2), and E2-
treated MCF-7 cells after 24 hours (bar 3). (b) Relative hASH-1 mRNA 
levels in synchronized, non-E2-treated MCF-7 cells (bar 1), non-E2-
treated MCF-7 cells after 24 hours (bar 2), and E2-treated MCF-7 cells 
after 24 hours (bar 3). All data are presented as mean values ± SD of 
three samples/bar. (c) Hes-6 protein in synchronized MCF-7 cells with-
out E2 (column 1), treated with E2 (column 2), and with both E2 and 
tamoxifen (column 3) for 24 hours.
Figure 5
siRNA against Hes-6 causes a reduction of E2F-1 mRNA. Relative 
Hes-6 (a) and E2F-1 mRNA levels (b) in MCF-7 cells transfected with 
50 nM siRNA against Hes-6 (siRNA-Hes-6) or luciferase as control 
(control). Graphs are presented as values relative to MCF-7 cells trans-
fected with the siRNA luciferase control vector. All bars represent mean 
values ± SD of three samples, and experiments were repeated twice 
with similar results. Significance is presented as *P < 0.05.Page 7 of 9
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is described.
As shown in Figure 3, expression of Hes-6 caused increased
proliferation in both the absence and the presence of E2, The
most probable explanation is that Hes-6 inhibits Hes-1,
thereby changing the expression of cell-cycle regulators. E2F-
1 might be particularly important in this context, because it is
strongly inhibited by Hes-1 at the transcriptional level [9]. In
agreement with this notion, expression of Hes-6 resulted in
induction of E2F-1 at both the mRNA and the protein levels,
whereas inhibition of Hes-6 by siRNA prevented the ERα-
mediated induction of E2F-1 (Figures 2 and 5).
In the xenograft experiments shown in Figure 3, the expression
of Hes-6 resulted in a dramatic increase of tumor growth, most
likely as a consequence of the proliferation-stimulatory func-
tion of Hes-6. However, expression of Hes-6 might also affect
xenograft growth in proliferation-independent pathways; for
example, Hes-6 might regulate angiogenesis and paracrine
growth factors. When Hes-6 was expressed in T47D cells, the
levels of both Hes-6 and E2F-1 was higher in the cells grown
as xenografts than in in vitro cultured cells (Figures 2 and 3).
A possible reason for this is that the three-dimensional in vivo
milieu and the presence of stromal factors stimulate Hes-6
expression further. We believe that alternative pathways can at
least partially overcome ER regulation in subtypes of breast
cancer.
The important role of E2F-factors in cancer has been investi-
gated by other researchers in great detail [8,20]. E2F-1 has
been studied as a potential marker in breast cancer diagnos-
tics. In one report, E2F-1 protein correlated with Mib1/Ki67
expression and was expressed at higher levels in advanced-
stage breast cancer [21]. High expression of E2F-1 also has
been shown in small cell lung cancer, and these tumors do not
express Hes-1. Conversely, non-small cell lung cancer
expresses lower levels of E2F-1 and higher levels of Hes-1,
indicating that Hes factors may be important in E2F-1 regula-
tion in these cancers as well [22].
As shown in Figure 4, E2 treatment of MCF-7 cells caused
increased expression of Hes-6 mRNA and protein. Because
MCF-7 cells contain only ERα, this effect should be mediated
through ERα. However, transient transfections of T47D and
MCF-7 cells with a Hes-6 promoter construct did not reveal
any ERα-mediated regulation (data not shown). Accordingly,
we speculate that an element upstream or downstream of the
proximal Hes-6 promoter is responsible for ERα-regulated
Hes-6 transcription.
In addition to Hes-6, we found that E2 treatment of MCF-7
cells resulted in increased hASH-1 expression. Moreover,
hASH-1 was expressed in response to Hes-6 in T47D cells.
Because hASH-1 is normally repressed by Hes-1 through an
element in its proximal promoter [23], it is likely that the induc-
tion of hASH-1 is a consequence of Hes-6 expression, leading
to inactivation of Hes-1. In tissues, Hes-6 and hASH-1 expres-
sion are often associated with each other. For instance, it was
recently shown that Hes-6 and hASH-1 correlate with more-
aggressive prostate cancer [15].
As shown in an earlier study, Hes-1 is repressed by ERα at the
transcriptional level [16]. We therefore suggest that E2 treat-
ment of ERα+ breast cancer cells leads to inactivation of Hes-
1, both directly and through the induction of Hes-6. However,
the role of ERβ in Hes-6 regulation is not known and must be
clarified in future studies. Interestingly, as shown in Figure 4,
treatment of MCF-7 cells with the selective estrogen-receptor
modulator (SERM) tamoxifen caused repression of Hes-6,
indicating that Hes-6 might work as a marker for tamoxifen
response in breast cancer cells. In addition, it is possible that
repression of Hes-6 could be important for the breast cancer-
suppressive effects of tamoxifen.
Conclusions
Based on our findings, we propose that Hes-6 has an impor-
tant role in the proliferation of breast cancer cells. Hes-6 is
expressed in low levels in normal breast tissue but is strongly
induced in breast cancer tissue. As an ERα-regulated gene,
Hes-6 constitutes a novel link between estrogen signaling and
the Hes family of proteins, which are involved in differentiation
and proliferation. Consequently, a better knowledge of this
signaling pathway could be important for the identification of
endocrine-resistant tumors. Furthermore, Hes-6 seems to be
essential in ERα-mediated induction of E2F-1, a critical step in
the G1/S-phase transition of the cell cycle. Hes-6 emerges as
a potential marker for breast cancer and might be a target for
novel treatments based on the Hes signaling pathway.
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